Biomarkers in Parkinson’s disease

References

• Fahn S, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Nutt J G, Wooten GF. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med.353(10), 1021–1027 (2005).
   PubMed Web of Science ®Google Scholar
• de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, vanderMeche FGA. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology45(12), 2143–2146 (2005).
   Google Scholar
• Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J. Neurol. Neurosurg. Psych.73(5), 529–534 (2002).
   PubMed Web of Science ®Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, Demets DL, Downing GJ, Hoth DF. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Michell AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain127, 1693–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Montgomery EB, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology52(4), 757–762 (1992).
   Google Scholar
• Mourao LF, Aguiar PMD, Ferraz FAP, Behlau MS, Ferraz HB. Acoustic voice assessment in Parkinson's disease patients submitted to posteroventral pallidotomy. Arquivos de Neuro-Psiquiatria63(1), 20–25 (2005).
   Google Scholar
• Nagulic M, Davidovic J, Nagulic I. Parkinsonian voice acoustic analysis in real-time after stereotactic thalamotomy. Stereot. Funct. Neurosurg.83(2–3), 115–121 (2003).
   Google Scholar
• Rascol O, Sabatini U, Simonettamoreau M, Montastruc JL, Rascol A, Clanet M. Square-wave jerks in parkinsonian syndromes. J. Neurol. Neurosurg. Psych.54(7), 599–602 (1991).
   PubMed Web of Science ®Google Scholar
• Hocherman S, Giladi N. Visuomotor control abnormalities in patients with unilateral parkinsonism. Neurology50(6), 1648–1654 (1998).
   PubMed Web of Science ®Google Scholar
• Chan F, Armstrong IT, Pari G, Riopelle RJ, Munoz DP. Deficits in saccadic eye-movement control in Parkinson's disease. Neuropsychologia43(5), 784–796 (2005).
   PubMed Web of Science ®Google Scholar
• Pinter MM, Helscher RJ, Nasel COJ, Riedl E, Schnaberth G. Quantification of motor deficit in Parkinsons-disease with a motor-performance test series.J. Neural. Transm. Park Dis. Dement. Sect.4(2), 131–141 (1992).
   PubMedGoogle Scholar
• Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov. Disord.17(4), 795–798 (2002).
   PubMed Web of Science ®Google Scholar
• Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol. Scand.91(4), 247–250 (1995).
   PubMed Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol.56(2), 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M. The role of radiotracer imaging in Parkinson disease. Neurology64(2), 208–215 (2005).
   PubMed Web of Science ®Google Scholar
• Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson's disease progression. J. Neurol.251, 9–13 (2004).
   Google Scholar
• Marek K, Jennings D, Seibyl J. Imaging the dopamine system to assess disease-modifying drugs – studies comparing dopamine agonists and levodopa. Neurology61(6), S43–S48 (2003).
   Google Scholar
• Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [F-18]dopa PET. J. Neurol. Neurosurg. Psych.64(3), 314–319 (1998).
   PubMed Web of Science ®Google Scholar
• Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (I-123) β-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome - unmasking an early diagnosis. Arch. Neurol.61(8), 1224–1229 (2004)
   PubMedGoogle Scholar
• Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol.252, 37–42 (2005).
   Google Scholar
• Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54(1), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord.18(8), 890–897 (2003).
   PubMed Web of Science ®Google Scholar
• Becker G, Berg D. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov. Disord.16(1), 23–32 (2001).
   Google Scholar
• Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology56(1), 13–17 (2001).
   PubMedGoogle Scholar
• Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J. Neurol. Neurosurg. Psych.76(3), 423–425 (2005).
   PubMed Web of Science ®Google Scholar
• Sommer U, Hummel T, Cormann K et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord.19(10), 1196–1202 (2004).
   PubMed Web of Science ®Google Scholar
• Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia-nigra in chronic Parkinsons-disease visualized by transcranial color-coded real-time sonography. Neurology45(1), 182–184 (1995).
   PubMed Web of Science ®Google Scholar
• Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J. Neural Transmission109(2), 191–196 (2002).
   PubMedGoogle Scholar
• Ruprecht-Dorfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage18(2), 416–422 (2003).
   PubMed Web of Science ®Google Scholar
• Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AHV, Marsden CD. Brain, skeletal-muscle and platelet homogenate mitochondrial-function in Parkinsons-disease. Brain115, 333–342 (1992).
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis.9(2), 244–248 (2002).
   PubMed Web of Science ®Google Scholar
• Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R. Low platelet mitochondrial complex-i and complex-Ii/Iii activity in early untreated Parkinsons-disease. Ann. Neurol.37(6), 714–722 (1995).
   PubMed Web of Science ®Google Scholar
• Factor SA, Ortof E, Dentinger MP, Mankes R, Barron KD. Platelet morphology in Parkinsons-disease – An electron-microscopic study. J. Neurol. Sciences122(1), 84–89 (1994).
   PubMed Web of Science ®Google Scholar
• Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. Platelet monoamine oxidase B and plasma β-phenylethylamine in Parkinson's disease. J. Neurol. Neurosurg. Psych.70(2), 229–231 (2001).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science276(5321), 2045–2047 (1997).
   PubMed Web of Science ®Google Scholar
• Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology47(1), 155–160 (1996).
   PubMed Web of Science ®Google Scholar
• Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R. Parkinson disease in twins – an etiologic study. JAMA281(4), 341–346 (1999).
   PubMed Web of Science ®Google Scholar
• Hernandez D, Ruiz CP, Crawley A, Malkani R, Werner J, Gwinn-Hardy K. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci. Lett.389(3), 137–139 (2005).
   Google Scholar
• Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med.354(4), 422–423 (2006).
   PubMed Web of Science ®Google Scholar
• Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM. Neuroprotective agents for clinical trials in Parkinson's disease – a systematic assessment. Neurology60(8), 1234–1240 (2003).
   PubMed Web of Science ®Google Scholar
• Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE. Cost–effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med.352(6), 570–585 (2005).
   PubMed Web of Science ®Google Scholar
• Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J. Neural Transmission108(7), 803–807 (2001).
   PubMed Web of Science ®Google Scholar
• Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Creange A, Remy P. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology61(4), 540–543 (2003).
   PubMed Web of Science ®Google Scholar
• Forman MS, Lee VMY, Trojanowski JQ. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron47(4), 479–482 (2005).
   Google Scholar
• Pankratz N, Foroud T. Genetics of Parkinson disease. NeuroRx1, 235–242 (2004).
   Google Scholar